Research progress on microRNAs as molecular markers in pancreatic cancer: a narrative review

Fu, Ruibiao; Chen, Xi; Chen, Yan; Ye, Qinghuang; Yang, Bin; Shao, Qian; Zhu, Jinhui

doi:10.21037/jgo-22-577

Cited by 3 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These small non-coding RNA molecules bind by complementarity to the 3 0 -UTR of target mRNAs, regulating therefore their expression at posttranscriptional and translational levels and subsequently controlling diverse biological processes, for example, embryonic development, fat storage, insulin secretion, drug metabolism, apoptosis, cell growth and tumorigenesis. [82][83][84][85][86][87] The involvement of liver miRNAs in the regulation of genes expression as a response to dioxin exposure was previous investigated over a restricted scale. [88][89][90] Thus, the current study was conducted to present a wider overview on the transcriptional pattern of miRNAs in the mouse liver after exposure to TCDD to determine the potential regulatory effects these miRNAs on the target mRNAs.…”

Section: Introductionmentioning

confidence: 99%

“…MicroRNAs (miRNAs) gained a considerable attention as effective and determinant suppressors for the expression of target mRNAs. These small non‐coding RNA molecules bind by complementarity to the 3′‐UTR of target mRNAs, regulating therefore their expression at posttranscriptional and translational levels and subsequently controlling diverse biological processes, for example, embryonic development, fat storage, insulin secretion, drug metabolism, apoptosis, cell growth and tumorigenesis 82–87 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Female‐to‐male differential transcription patterns of miRNA‐mRNA networks in the livers of dioxin‐exposed mice

Hammoudeh

Soukkarieh

Murphy

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

Non‐coding microRNAs (miRNAs) have important roles in regulating the expression of liver mRNAs in response to xenobiotic‐exposure, but their roles concerning dioxins such as TCDD (2,3,7,8‐Tetrachlorodibenzo‐p‐dioxin) are less clear. This report concerns the potential implication of liver (class I) and circulating (class II) miRNAs in hepatotoxicity of female and male mice after acute exposure to TCDD. The data show that, of a total of 38 types of miRNAs, the expression of eight miRNAs were upregulated in both female and male mice exposed to TCDD. Inversely, the expression of nine miRNAs were significantly downregulated in both animal genders. Moreover, certain miRNAs were preferentially induced in either females or males. The potential downstream regulatory effects of miRNAs on their target genes was evaluated by determining the expression of three group of genes that are potentially involved in cancer biogenesis, other diseases and in hepatotoxicity. It was found that certain cancer‐related genes were more highly expressed females rather than males after exposure to TCDD. Furthermore, a paradoxical female‐to‐male transcriptional pattern was found for several disease‐related and hepatotoxicity‐related genes. These results suggest the possibility of developing of new miRNA‐specific interfering molecules to address their dysfunctions as caused by TCDD.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Female‐to‐male differential transcription patterns of miRNA‐mRNA networks in the livers of dioxin‐exposed mice

Hammoudeh

Soukkarieh

Murphy

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

show abstract

MicroRNA-409: Molecular functions and clinical applications in cancer

Rajabloo,

Latifi,

Akhlaghipour

et al. 2024

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

Analysis of association between new-onset type 2 diabetes mellitus and pancreatic cancer: retrospective research

Ponomarev,

Moiseenko,

Pavlovsky

et al. 2024

Perm Medical Journal

View full text Add to dashboard Cite

Introduction. Pancreatic cancer is characterized by an extremely unsatisfactory prognosis, despite the development of technologies for the treatment of this pathology. In more than 80 % of patients at the time of the initial request for medical care, the disease is represented by a locally advanced or metastatic stage. Currently used methods of treatment of this nosology are most effective at the early stages of the disease. The absence of characteristic clinical, instrumental and laboratory symptoms, as well as organizational measures for the early detection of this neoplasia creates certain difficulties for effective treatment. Type 2 diabetes is probably one of the risk factors for the development of pancreatic cancer. Epidemiological studies have shown that newly diagnosed type 2 diabetes is associated with a 1.5–2.0-fold increased risk of developing pancreatic cancer in patients over 50 years of age. Insulin resistance and its associated hyperglycemia, hyperinsulinemia, and inflammation are thought to be the main mechanisms contributing to the development of diabetes-related pancreatic cancer. New-onset type 2 diabetes mellitus may be a preclinical sign of pancreatic cancer, and patients with newly diagnosed diabetes may constitute a population in which pancreatic cancer can be detected at an early stage, that will significantly improve the results of treatment. Objective. To analyze the relationship between new-onset type 2 diabetes mellitus and the development of pancreatic cancer. Material and methods. A retrospective analysis of the medical records of patients with a confirmed diagnosis of pancreatic cancer, who were treated at the Academician A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies from 2019 to 2022, was carried out. As a source of information, data from medical records of inpatient and outpatient treatment cards were used. In total, the data of 203 persons were studied: morphologically confirmed pancreatic ductal adenocarcinoma was diagnosed in 172 patients (group I), in 31 patients pancreatic tumors had a different histological structure: acinar carcinoma, neuroendocrine tumors (group II). Group I excluded 8 patients without diabetes mellitus who were taking medications, which affect the blood glucose levels. The frequency of occurrence of type 2 diabetes mellitus in the groups was analyzed and then the statistical significance was assessed using the calculation of Fisher's exact test. Group I was analyzed by sex and age, then patients from group I aged 50–75 years were divided into 3 subgroups depending on the glycemic profile: 1) patients with long-term type 2 diabetes mellitus (anamnesis more than 3 years); 2) patients with new-onset type 2 diabetes mellitus (anamnesis less than 3 years); 3) patients without disorders of glucose metabolism. In the subgroup of patients with a long history of type 2 diabetes mellitus, the fact of disease decompensation was additionally assessed. Results. Type 2 diabetes mellitus was more common in patients with pancreatic ductal adenocarcinoma (p 0.01, Fisher's exact test p = 0.0012) than in other pancreatic neoplasms. The age of patients in group I ranged from 36 to 81 years. The average age of men was 61 ± 8.5 years. The average age of women was 58.9 ± 8.2 years. Among patients of group I aged 50–75 years, new-onset type 2 diabetes mellitus occurred in 78 (68.4 %) persons, type 2 diabetes mellitus with an anamnesis of more than 3 years was detected in 19 (16.6 %) patients, normal metabolism of glucose was observed in 17 (14 %) patients. Of 19 patients with a long anamnesis of type 2 diabetes mellitus (more than 3 years), decompensation in the form of impaired glycemic control was observed in 12 (63.2 %) patients before the diagnosis of pancreatic cancer, in 7 (36.8 %) patients no signs of decompensation of the course of type 2 diabetes mellitus were registered. Conclusions. New-onset type 2 diabetes mellitus occurred in 78 (64.4 %) patients over 50 years of age with pancreatic ductal adenocarcinoma. The data obtained indicate the feasibility of conducting studies to identify patients aged 50–70 years with newly diagnosed type 2 diabetes in the risk group for the development of pancreatic cancer and examine this contingent at the stage of primary health care. Further retrospective as well as prospective multicenter studies on the association between newly diagnosed type 2 diabetes mellitus and the risk of developing pancreatic cancer are required.

show abstract

Research progress on microRNAs as molecular markers in pancreatic cancer: a narrative review

Cited by 3 publications

References 56 publications

Female‐to‐male differential transcription patterns of miRNA‐mRNA networks in the livers of dioxin‐exposed mice

Female‐to‐male differential transcription patterns of miRNA‐mRNA networks in the livers of dioxin‐exposed mice

MicroRNA-409: Molecular functions and clinical applications in cancer

Analysis of association between new-onset type 2 diabetes mellitus and pancreatic cancer: retrospective research

Contact Info

Product

Resources

About